CSF2 and neuroblastoma: Furthermore, the overall clinical response of neuroblastoma patients has been found to be further improved by the addition of granulocyte-macrophage colony-stimulating factor (GM-CSF), acting on myeloid cells including neutrophils, to the anti-GD2 treatment regime [14,21,22,23,24].